These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37291502)

  • 1. Incidence and risk factors of pneumococcal pneumonia in adults: a population-based study.
    Ochoa-Gondar O; Torras-Vives V; de Diego-Cabanes C; Satué-Gracia EM; Vila-Rovira A; Forcadell-Perisa MJ; Ribas-Seguí D; Rodríguez-Casado C; Vila-Córcoles A
    BMC Pulm Med; 2023 Jun; 23(1):200. PubMed ID: 37291502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Risk of Pneumococcal Pneumonia in Adults with Distinct Underlying Medical Conditions: A Population-Based Study.
    Vila-Corcoles A; Ochoa-Gondar O; Vila-Rovira A; Aragon M; Esteban-Julvez L; Chamorro N; Hospital I; Satue E; Blade J; de Diego C; Gomez-Bertomeu F; Raga X
    Lung; 2020 Jun; 198(3):481-489. PubMed ID: 32253492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Population-based incidence of hospitalised pneumococcal pneumonia in adults with distinct baseline risk strata in Catalonia throughout 2015, the EPIVAC study.].
    Vila Córcoles Á; Hospital Guardiola I; Ochoa Gondar O; Vila Rovira Á; Aragón Pérez M; Satué Gracia E
    Rev Esp Salud Publica; 2019 Apr; 93():. PubMed ID: 31313756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology of pneumococcal pneumonia among middle-aged and older adults in Catalonia, 2017-2018].
    Ochoa-Gondar O; Torras-Vives V; de Diego-Cabanes C; Satué Gracia E; Forcadell-Peris MJ; Vila-Córcoles Á
    Aten Primaria; 2023 Jul; 55(7):102631. PubMed ID: 37119778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults.
    Vila-Corcoles A; Aguirre-Chavarria C; Ochoa-Gondar O; de Diego C; Rodriguez-Blanco T; Gomez F; Raga X; Barnes L; Magarolas R; Esteban L
    Infection; 2015 Dec; 43(6):699-706. PubMed ID: 26037386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of high, medium and low-risk medical conditions for pneumococcal vaccination in Catalonian middle-aged and older adults: a population-based study.
    Ochoa-Gondar O; Hospital I; Vila-Corcoles A; Aragon M; Jariod M; de Diego C; Satue E;
    BMC Public Health; 2017 Jun; 17(1):610. PubMed ID: 28662648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.
    Weycker D; Farkouh RA; Strutton DR; Edelsberg J; Shea KM; Pelton SI
    BMC Health Serv Res; 2016 May; 16():182. PubMed ID: 27177430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015-2016.
    Vila-Corcoles A; Hospital I; Ochoa-Gondar O; Satue E; de Diego C; Vila-Rovira A; Gómez-Bertomeu F; Raga X; Aragón M
    Vaccine; 2020 Jan; 38(5):1170-1180. PubMed ID: 31759735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study.
    Vila-Corcoles A; Ochoa-Gondar O; de Diego C; Satue E; Aragón M; Vila-Rovira A; Gomez-Bertomeu F; Magarolas R; Figuerola-Massana E; Raga X; Perez MO; Ballester F
    BMC Infect Dis; 2018 Apr; 18(1):196. PubMed ID: 29699550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases.
    Imai K; Petigara T; Kohn MA; Nakashima K; Aoshima M; Shito A; Kanazu S
    BMJ Open; 2018 Mar; 8(3):e018553. PubMed ID: 29500201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumonia hospitalisation and case-fatality rates in older Australians with and without risk factors for pneumococcal disease: implications for vaccine policy.
    Dirmesropian S; Liu B; Wood JG; MacIntyre CR; McIntyre P; Karki S; Jayasinghe S; Newall AT
    Epidemiol Infect; 2019 Jan; 147():e118. PubMed ID: 30869015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence.
    Curcio D; Cané A; Isturiz R
    Int J Infect Dis; 2015 Aug; 37():30-5. PubMed ID: 25997673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline in Pneumococcal Disease Attenuated in Older Adults and Those With Comorbidities Following Universal Childhood PCV13 Immunization.
    Pelton SI; Bornheimer R; Doroff R; Shea KM; Sato R; Weycker D
    Clin Infect Dis; 2019 May; 68(11):1831-1838. PubMed ID: 30239637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and case fatality rates of community-acquired pneumonia and pneumococcal diseases among Korean adults: Catchment population-based analysis.
    Heo JY; Seo YB; Choi WS; Lee J; Yoon JG; Lee SN; Choi MJ; Noh JY; Ahn JY; Jeong HW; Cheong HJ; Kim WJ; Lee HY; Song JY
    PLoS One; 2018; 13(3):e0194598. PubMed ID: 29596444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
    Albrich WC; Baughman W; Schmotzer B; Farley MM
    Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections.
    Grau I; Ardanuy C; Calatayud L; Schulze MH; Liñares J; Pallares R
    Int J Infect Dis; 2014 Aug; 25():59-64. PubMed ID: 24853638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimates of Target Population for Pneumococcal Vaccination in People over 50 years in Catalonia and Spain].
    Vila-Córcoles A; Ochoa-Gondar O; Satué E; de Diego C; Vila-Rovira M; Jariod M
    Rev Esp Salud Publica; 2017 Mar; 91():. PubMed ID: 28300793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease.
    Yildirim I; Shea KM; Little BA; Silverio AL; Pelton SI;
    Pediatrics; 2015 Mar; 135(3):495-503. PubMed ID: 25647674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus-Infected Individuals in a High-income Setting.
    Garcia Garrido HM; Mak AMR; Wit FWNM; Wong GWM; Knol MJ; Vollaard A; Tanck MWT; Van Der Ende A; Grobusch MP; Goorhuis A
    Clin Infect Dis; 2020 Jun; 71(1):41-50. PubMed ID: 31634398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort.
    Sohn S; Hong K; Chun BC
    Int J Infect Dis; 2020 Apr; 93():146-150. PubMed ID: 31982620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.